Elmind Capital’s Nurix Therapeutics NRIX Stock Holding History

Elmind Capital’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.2M	Hold	460,000	–	–	2.8%	14
2026 Q1	$7.13M	Hold	460,000	–	–	2.02%	16
2025 Q4	$8.73M	Buy	+460,000	New	+$6.61M	2.58%	14

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Elmind Capital's NRIX Position: Q2 2026 in Review

Elmind Capital held its Nurix Therapeutics (NRIX) position steady in Q2 2026 at 460,000 shares worth $11.2M. The position accounts for 2.8% of the portfolio, ranked #14.

Elmind Capital first reported a position in NRIX in Q4 2025 and has held it in 3 quarters since. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

Elmind Capital held 460,000 shares of Nurix Therapeutics worth $11.2M as of Q2 2026.
Elmind Capital left its Nurix Therapeutics share count unchanged in Q2 2026.
Nurix Therapeutics made up 2.8% of Elmind Capital's portfolio in Q2 2026, its #14 holding.
Elmind Capital first reported a position in Nurix Therapeutics in Q4 2025 and has held it in 3 quarters since.
211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Elmind Capital's 13F filing for Q2 2026, filed 14 Aug 2026.